Antipsychotics and Amotivation

Gagan Fervaha, Hiroyoshi Takeuchi, Jimmy Lee, George Foussias, Paul J. Fletcher, Ofer Agid, Gary Remington

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Antipsychotic drugs are thought to produce secondary negative symptoms, which can also exacerbate primary negative symptoms. In the present study, we examined whether motivational deficits in particular were related to antipsychotic treatment in patients with schizophrenia in a dose-dependent manner. Five hundred and twenty individuals with schizophrenia who were receiving antipsychotic monotherapy for at least 6 months and followed prospectively were included in the present study. Participants were receiving one of five antipsychotic medications (olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone), and analyses were conducted for patients receiving each drug separately. Analysis of covariance models were constructed to examine the effect of antipsychotic dose on level of motivational impairment, controlling for selected demographic and clinical variables (eg, positive symptoms). Level of motivation, or deficits therein, were evaluated using a derived measure from the Quality of Life Scale, and in addition with scores derived from the Positive and Negative Syndrome Scale. Antipsychotic dose was not related to the level of amotivation for any of the medications examined. Moreover, severity of sedation was not significantly related to the degree of amotivation. One hundred and twenty-one individuals were identified as antipsychotic-free at baseline, and after 6 months of antipsychotic treatment, no change in motivation was found. Chronic treatment with antipsychotics does not necessarily impede or enhance goal-directed motivation in patients with schizophrenia. It is possible that the negative impact of antipsychotics in this regard is overstated; conversely, the present results also indicate that we must look beyond antipsychotics in our efforts to improve motivation.

Original languageEnglish
Pages (from-to)1539-1548
Number of pages10
JournalNeuropsychopharmacology
Volume40
Issue number6
DOIs
Publication statusPublished - 2015 May 1
Externally publishedYes

Fingerprint

Antipsychotic Agents
Motivation
Schizophrenia
olanzapine
Perphenazine
Risperidone
Therapeutics
Quality of Life
Demography

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Fervaha, G., Takeuchi, H., Lee, J., Foussias, G., Fletcher, P. J., Agid, O., & Remington, G. (2015). Antipsychotics and Amotivation. Neuropsychopharmacology, 40(6), 1539-1548. https://doi.org/10.1038/npp.2015.3

Antipsychotics and Amotivation. / Fervaha, Gagan; Takeuchi, Hiroyoshi; Lee, Jimmy; Foussias, George; Fletcher, Paul J.; Agid, Ofer; Remington, Gary.

In: Neuropsychopharmacology, Vol. 40, No. 6, 01.05.2015, p. 1539-1548.

Research output: Contribution to journalArticle

Fervaha, G, Takeuchi, H, Lee, J, Foussias, G, Fletcher, PJ, Agid, O & Remington, G 2015, 'Antipsychotics and Amotivation', Neuropsychopharmacology, vol. 40, no. 6, pp. 1539-1548. https://doi.org/10.1038/npp.2015.3
Fervaha G, Takeuchi H, Lee J, Foussias G, Fletcher PJ, Agid O et al. Antipsychotics and Amotivation. Neuropsychopharmacology. 2015 May 1;40(6):1539-1548. https://doi.org/10.1038/npp.2015.3
Fervaha, Gagan ; Takeuchi, Hiroyoshi ; Lee, Jimmy ; Foussias, George ; Fletcher, Paul J. ; Agid, Ofer ; Remington, Gary. / Antipsychotics and Amotivation. In: Neuropsychopharmacology. 2015 ; Vol. 40, No. 6. pp. 1539-1548.
@article{f4e51e0a536a46e3812641f80f26c68c,
title = "Antipsychotics and Amotivation",
abstract = "Antipsychotic drugs are thought to produce secondary negative symptoms, which can also exacerbate primary negative symptoms. In the present study, we examined whether motivational deficits in particular were related to antipsychotic treatment in patients with schizophrenia in a dose-dependent manner. Five hundred and twenty individuals with schizophrenia who were receiving antipsychotic monotherapy for at least 6 months and followed prospectively were included in the present study. Participants were receiving one of five antipsychotic medications (olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone), and analyses were conducted for patients receiving each drug separately. Analysis of covariance models were constructed to examine the effect of antipsychotic dose on level of motivational impairment, controlling for selected demographic and clinical variables (eg, positive symptoms). Level of motivation, or deficits therein, were evaluated using a derived measure from the Quality of Life Scale, and in addition with scores derived from the Positive and Negative Syndrome Scale. Antipsychotic dose was not related to the level of amotivation for any of the medications examined. Moreover, severity of sedation was not significantly related to the degree of amotivation. One hundred and twenty-one individuals were identified as antipsychotic-free at baseline, and after 6 months of antipsychotic treatment, no change in motivation was found. Chronic treatment with antipsychotics does not necessarily impede or enhance goal-directed motivation in patients with schizophrenia. It is possible that the negative impact of antipsychotics in this regard is overstated; conversely, the present results also indicate that we must look beyond antipsychotics in our efforts to improve motivation.",
author = "Gagan Fervaha and Hiroyoshi Takeuchi and Jimmy Lee and George Foussias and Fletcher, {Paul J.} and Ofer Agid and Gary Remington",
year = "2015",
month = "5",
day = "1",
doi = "10.1038/npp.2015.3",
language = "English",
volume = "40",
pages = "1539--1548",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Antipsychotics and Amotivation

AU - Fervaha, Gagan

AU - Takeuchi, Hiroyoshi

AU - Lee, Jimmy

AU - Foussias, George

AU - Fletcher, Paul J.

AU - Agid, Ofer

AU - Remington, Gary

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Antipsychotic drugs are thought to produce secondary negative symptoms, which can also exacerbate primary negative symptoms. In the present study, we examined whether motivational deficits in particular were related to antipsychotic treatment in patients with schizophrenia in a dose-dependent manner. Five hundred and twenty individuals with schizophrenia who were receiving antipsychotic monotherapy for at least 6 months and followed prospectively were included in the present study. Participants were receiving one of five antipsychotic medications (olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone), and analyses were conducted for patients receiving each drug separately. Analysis of covariance models were constructed to examine the effect of antipsychotic dose on level of motivational impairment, controlling for selected demographic and clinical variables (eg, positive symptoms). Level of motivation, or deficits therein, were evaluated using a derived measure from the Quality of Life Scale, and in addition with scores derived from the Positive and Negative Syndrome Scale. Antipsychotic dose was not related to the level of amotivation for any of the medications examined. Moreover, severity of sedation was not significantly related to the degree of amotivation. One hundred and twenty-one individuals were identified as antipsychotic-free at baseline, and after 6 months of antipsychotic treatment, no change in motivation was found. Chronic treatment with antipsychotics does not necessarily impede or enhance goal-directed motivation in patients with schizophrenia. It is possible that the negative impact of antipsychotics in this regard is overstated; conversely, the present results also indicate that we must look beyond antipsychotics in our efforts to improve motivation.

AB - Antipsychotic drugs are thought to produce secondary negative symptoms, which can also exacerbate primary negative symptoms. In the present study, we examined whether motivational deficits in particular were related to antipsychotic treatment in patients with schizophrenia in a dose-dependent manner. Five hundred and twenty individuals with schizophrenia who were receiving antipsychotic monotherapy for at least 6 months and followed prospectively were included in the present study. Participants were receiving one of five antipsychotic medications (olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone), and analyses were conducted for patients receiving each drug separately. Analysis of covariance models were constructed to examine the effect of antipsychotic dose on level of motivational impairment, controlling for selected demographic and clinical variables (eg, positive symptoms). Level of motivation, or deficits therein, were evaluated using a derived measure from the Quality of Life Scale, and in addition with scores derived from the Positive and Negative Syndrome Scale. Antipsychotic dose was not related to the level of amotivation for any of the medications examined. Moreover, severity of sedation was not significantly related to the degree of amotivation. One hundred and twenty-one individuals were identified as antipsychotic-free at baseline, and after 6 months of antipsychotic treatment, no change in motivation was found. Chronic treatment with antipsychotics does not necessarily impede or enhance goal-directed motivation in patients with schizophrenia. It is possible that the negative impact of antipsychotics in this regard is overstated; conversely, the present results also indicate that we must look beyond antipsychotics in our efforts to improve motivation.

UR - http://www.scopus.com/inward/record.url?scp=84940006894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940006894&partnerID=8YFLogxK

U2 - 10.1038/npp.2015.3

DO - 10.1038/npp.2015.3

M3 - Article

VL - 40

SP - 1539

EP - 1548

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 6

ER -